In The News Posted February 7, 2020 Share Posted February 7, 2020 LEIDEN, Netherlands, Feb. 7, 2020 /PRNewswire/ -- Pharvaris B.V., a clinical-stage company focused on the discovery and development of novel oral B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other B2-receptor-mediated indications, has appointed Peng Lu, M.D.... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.